Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

282 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Calculating the net clinical benefit in neuro-oncology clinical trials using two methods: quality-adjusted survival effect sizes and joint modeling.
Coomans MB, Dirven L, Aaronson NK, Baumert BG, van den Bent M, Bottomley A, Brandes AA, Chinot O, Coens C, Gorlia T, Herrlinger U, Keime-Guibert F, Malmström A, Martinelli F, Sloan JA, Stupp R, Talacchi A, Weller M, Wick W, Reijneveld JC, Taphoorn MJB. Coomans MB, et al. Among authors: herrlinger u. Neurooncol Adv. 2020 Oct 29;2(1):vdaa147. doi: 10.1093/noajnl/vdaa147. eCollection 2020 Jan-Dec. Neurooncol Adv. 2020. PMID: 33409496 Free PMC article.
Treosulfan chemotherapy for recurrent malignant glioma.
Schmidt F, Wick W, Herrlinger U, Dichgans J, Weller M. Schmidt F, et al. Among authors: herrlinger u. J Neurooncol. 2000 Sep;49(3):231-4. doi: 10.1023/a:1006496831144. J Neurooncol. 2000. PMID: 11212902 Clinical Trial.
Gliomatosis cerebri: molecular pathology and clinical course.
Herrlinger U, Felsberg J, Küker W, Bornemann A, Plasswilm L, Knobbe CB, Strik H, Wick W, Meyermann R, Dichgans J, Bamberg M, Reifenberger G, Weller M. Herrlinger U, et al. Ann Neurol. 2002 Oct;52(4):390-9. doi: 10.1002/ana.10297. Ann Neurol. 2002. PMID: 12325066
SD-208, a novel transforming growth factor beta receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo.
Uhl M, Aulwurm S, Wischhusen J, Weiler M, Ma JY, Almirez R, Mangadu R, Liu YW, Platten M, Herrlinger U, Murphy A, Wong DH, Wick W, Higgins LS, Weller M. Uhl M, et al. Among authors: herrlinger u. Cancer Res. 2004 Nov 1;64(21):7954-61. doi: 10.1158/0008-5472.CAN-04-1013. Cancer Res. 2004. PMID: 15520202
282 results